Cigna Tops Q2 Estimates and Lifts Full-Year EPS Target to at Least $30.45
CI sits 21% above its 52-week low of $239.51.
Summary
Cigna posted Q2 2026 adjusted EPS of $7.78, an 8% year-over-year increase, and raised its full-year guidance to at least $30.45. Revenue grew 7% to $71.7 billion, fueled by pharmacy and premium growth.
Key Events · Earnings and Guidance · CI
-
Q2 Earnings Beat
Adjusted EPS came in at $7.78, up from $7.20 a year ago, on revenue of $71.7 billion—a 7% increase.
-
Full-Year Guidance Raised
The outlook was lifted to at least $30.45 per share, up from the prior implied range, signaling confidence in the back half of 2026.
-
Healthcare Segment Strength
Pre-tax adjusted income in Cigna Healthcare rose 17% to $1.28 billion, driven by improved margins in the U.S. Employer business.
-
Evernorth Income Dip
Pre-tax adjusted income fell 2% to $1.66 billion, pressured by client-focused initiatives and lower claims volume, though growth in Specialty and Care Services provided a partial offset.
Analysis · CI · Finance
A strong second quarter saw revenue climb 7% to $71.7 billion and adjusted EPS reach $7.78, comfortably ahead of the $7.20 posted a year ago. Reflecting that momentum, management raised the full-year adjusted EPS outlook to at least $30.45. The healthcare segment was the standout, delivering a 17% jump in pre-tax adjusted income, even as the medical care ratio edged up 130 basis points. Evernorth's income slipped 2%, weighed down by investments in client-focused initiatives. Taken together, the results underscore Cigna's ability to expand earnings while navigating cost pressures and a strategic repositioning that includes the planned exit from Individual and Family Plans in 2027.
At the time of this filing, CI was trading at $289.89 on NYSE in the Finance sector, with a market capitalization of approximately $76.7B. The 52-week trading range was $239.51 to $315.47. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.